Erste Asset Management GmbH Has $8.62 Million Stock Holdings in Biogen Inc. $BIIB

Erste Asset Management GmbH raised its position in Biogen Inc. (NASDAQ:BIIB) by 6.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 48,734 shares of the biotechnology company’s stock after buying an additional 3,149 shares during the quarter. Erste Asset Management GmbH’s holdings in Biogen were worth $8,618,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in BIIB. WPG Advisers LLC grew its holdings in Biogen by 417.9% in the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 117 shares in the last quarter. Accredited Wealth Management LLC grew its holdings in Biogen by 1,233.3% in the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 185 shares in the last quarter. First Horizon Corp acquired a new position in Biogen in the 4th quarter valued at $30,000. WFA of San Diego LLC acquired a new position in Biogen in the 2nd quarter valued at $32,000. Finally, Root Financial Partners LLC grew its holdings in Biogen by 198.4% in the 4th quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 123 shares in the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

Biogen Price Performance

Shares of BIIB stock opened at $192.62 on Tuesday. The company has a quick ratio of 2.41, a current ratio of 3.06 and a debt-to-equity ratio of 0.34. Biogen Inc. has a twelve month low of $121.05 and a twelve month high of $205.97. The company has a market cap of $28.44 billion, a P/E ratio of 20.67 and a beta of 0.20. The business has a fifty day simple moving average of $187.63 and a 200 day simple moving average of $183.63.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, topping the consensus estimate of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The business had revenue of $2.48 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same period in the prior year, the company earned $3.02 EPS. Biogen’s revenue for the quarter was up 1.9% on a year-over-year basis. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, sell-side analysts forecast that Biogen Inc. will post 14.18 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have commented on BIIB. UBS Group raised Biogen from a “neutral” rating to a “buy” rating and upped their price objective for the company from $185.00 to $225.00 in a report on Wednesday, April 22nd. Weiss Ratings upgraded Biogen from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, May 1st. Barclays started coverage on Biogen in a research report on Thursday, February 19th. They set an “equal weight” rating and a $185.00 target price for the company. Piper Sandler reiterated an “overweight” rating and set a $225.00 target price (up from $214.00) on shares of Biogen in a research report on Friday, May 15th. Finally, Tudor Pickering set a $201.00 target price on Biogen in a research report on Monday, February 9th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $217.26.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.